Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

There is an increasing role for biological markers (biomarkers) in the understanding and
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …

Second-generation anti-amyloid monoclonal antibodies are emerging as a viable
therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's …

Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing
years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a …

Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ)
immunoglobulin (Ig) G4 monoclonal antibody, on biomarkers of amyloid pathology …

Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis
is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the …

Introduction: While the prevalence of neurodegenerative diseases associated with dementia
such as Alzheimer's disease (AD) increases, our knowledge on the underlying mechanisms …

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people
around the world. The two main pathological mechanisms underlying the disease are beta …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects memory,
thinking, behavior, and other cognitive functions. Although there is no cure, detecting AD …